Upadacitinib for Active Non-Radiographic Axial Spondyloarthritis: 2-Year Study Results
Study Overview
The SELECT-AXIS 2 study showed that upadacitinib significantly improved symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) over 52 weeks compared to a placebo. This report evaluates its effectiveness and safety over 2 years.
Study Details
Eligible adult patients with nr-axSpA were enrolled based on specific criteria. They were randomly assigned to receive either upadacitinib (15 mg daily) or a placebo for the first year. After 52 weeks, all patients switched to upadacitinib. The study tracked results for 104 weeks, focusing on various health measures and any side effects.
Key Findings
Out of 313 patients, 224 completed the 2-year treatment. Those on continuous upadacitinib showed:
- Improvement in disease activity, pain, function, and quality of life.
- At week 104, 57.1% achieved significant improvement (ASAS40 response).
- Upadacitinib was well tolerated with low rates of serious side effects.
Conclusions
Upadacitinib consistently improved health outcomes over 2 years without new safety concerns.
Clinical Implications
Clinical trials are essential for developing safe treatments. Our AI platform, DocSym, helps integrate clinical standards and research, making it easier for healthcare providers to access vital information.
Enhancing Patient Care
In today’s healthcare landscape, efficiency is key. Our mobile apps facilitate scheduling, treatment monitoring, and telemedicine, improving patient management and expanding digital services.
By leveraging AI, clinics can streamline operations, enhance patient outcomes, and reduce paperwork. Discover more at aidevmd.com.
